EUVIMEDEUVIMED entdecken
Crossref

Oral fusidic acid for the treatment of mild‐to‐moderate hidradenitis suppurativa

Antonia Wiala iD, Sophie M Daschl, Theresa Stockinger, Klemens Rappersberger, Christian Posch

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Antonia Wiala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Clinic Landstrasse, Vienna, Austria. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Fusidic Acid, Severity of Illness Index, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a debilitating inflammatory skin disease. Tetracyclines are one of the few therapeutic options recommended for mild‐to‐moderate disease. This study aimed to investigate the efficacy of systemic fusidic acid's (FA) effectiveness in treating HS.

Methods

This retrospective study analyzed 55 FA therapy cycles (TC, average weekly dose: 6409 mg; range: 5250–9800 mg; 2–12 weeks) in 49 patients. The outcome was evaluated using the Physician's Global Assessment (PGA) scale. Therapy response was defined as any reduction of inflammatory activity without the occurrence of flares. We also characterized adverse events and investigated predictors for treatment success. Results were compared to a matched control group receiving doxycycline.

Results

FA treatment (55 treatment cycles (TC); male: 45.5%; female: 54.5%) showed an overall response rate of 70.9% (39 TC). No worsening was observed. Significantly higher response rates were observed in females (83.3%, P = 0.026) and Hurley I (90.9%, P = 0.008). After multivariate adjustment, higher response rates were associated with the Hurley grade ( P = 0.046) but not with gender ( P = 0.0174). Adverse reactions (21.8% gastrointestinal symptoms) occurred in 27.3% (15 TC) and 46.7% within the first 4 weeks. Similar results were observed in the doxycycline control group (overall response rate: 76.4%).

Conclusion

Oral FA is safe and improves symptoms in most patients. HS patients could benefit from oral FA treatment, especially in case of contraindications or resistance to tetracyclines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaFusidic AcidSeverity of Illness IndexAnti-Bacterial AgentsHumansFemaleMaleAdultRetrospective StudiesAdministration, OralMiddle AgedTreatment OutcomeDoxycyclineYoung AdultSex FactorsCase-Control Studies

Stichwörter der Autor:innen

antibioticsfusidic acidhidradenitis suppurativatherapeutic studies

Substanzen

Fusidic AcidAnti-Bacterial AgentsDoxycycline

Autor:innen und Institutionen

  • Department of Dermatology, Clinic Landstrasse, Vienna, Austria.
  • School of Medicine, Sigmund Freud University, Vienna, Austria.
  • Department of Dermatology, Clinic Hietzing, Vienna, Austria.
  • Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Munich, Germany.

ORCID-Profile: Antonia Wiala

Zitieren

APA

Wiala, A., Daschl, S. M., Stockinger, T., Rappersberger, K., & Posch, C. (2024). Oral fusidic acid for the treatment of mild‐to‐moderate hidradenitis suppurativa. International Journal of Dermatology. https://doi.org/10.1111/ijd.17115

Vancouver

Wiala A, Daschl SM, Stockinger T, Rappersberger K, Posch C. Oral fusidic acid for the treatment of mild‐to‐moderate hidradenitis suppurativa. International Journal of Dermatology. 2024. doi:10.1111/ijd.17115

BibTeX
@article{Wiala2024,
  author = {Wiala, Antonia and Daschl, Sophie M and Stockinger, Theresa and Rappersberger, Klemens and Posch, Christian},
  title = {Oral fusidic acid for the treatment of mild‐to‐moderate hidradenitis suppurativa},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17115}
}
Kostenlos starten →